RecruitingNot applicableNCT07014020
RB001 Gene Therapy Study in Children With SHANK3-related Phelan McDermid Syndrome (PMS)
Studying Phelan-McDermid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University First Hospital
- Intervention
- RB001(genetic)
- Enrollment
- 8 enrolled
- Eligibility
- 3-18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- Peking University First Hospital, Beijing, Beijing Municipality, China
Collaborators
Shenzhen Reborngene Therapeutics Co., Ltd. · Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07014020 on ClinicalTrials.govOther trials for Phelan-McDermid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07281079A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid SyndromeNeuren Pharmaceuticals Limited
- RECRUITINGPHASE1, PHASE2NCT06662188JAG201 Gene Therapy Study in Children & Adults With SHANK3 HaploinsufficiencyJaguar Gene Therapy, LLC
- ACTIVE NOT RECRUITINGNCT02461420Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid SyndromeBoston Children's Hospital